Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.2904
-0.1797 (-38.23%)
At close: Jan 14, 2026, 4:00 PM EST
0.3148
+0.0244 (8.40%)
After-hours: Jan 14, 2026, 7:59 PM EST
Plus Therapeutics Employees
Plus Therapeutics had 21 employees as of December 31, 2024. The number of employees increased by 1 or 5.00% compared to the previous year.
Employees
21
Change (1Y)
1
Growth (1Y)
5.00%
Revenue / Employee
$250,381
Profits / Employee
-$979,810
Market Cap
39.91M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 21 | 1 | 5.00% |
| Dec 31, 2023 | 20 | 3 | 17.65% |
| Dec 31, 2022 | 17 | 3 | 21.43% |
| Dec 31, 2021 | 14 | 2 | 16.67% |
| Dec 31, 2020 | 12 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PSTV News
- 12 hours ago - Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges - Benzinga
- 15 hours ago - Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering - GlobeNewsWire
- 6 days ago - Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Expands CNSide Assay Platform to State of California - GlobeNewsWire
- 5 weeks ago - Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants - GlobeNewsWire
- 5 weeks ago - Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting - GlobeNewsWire
- 6 weeks ago - Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 7 weeks ago - Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases - GlobeNewsWire